within Pharmacolibrary.Drugs.N_NervousSystem.N05A_Antipsychotics.N05AX17_Pimavanserin;

model Pimavanserin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.74,
    Cl = 7.5e-06,
    adminDuration = 600,
    adminMass = 34 / 1000000,
    adminCount = 1,
    Vd = 2.173,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.00635,
    Tlag = 10.200000000000001,
    Vdp = 1.59,
    k12 = 0.00014666666666666666,
    k21 = 0.00014666666666666666);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Pimavanserin</td></tr><tr><td>ATC code:</td><td>N05AX17</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>34</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2173</td><td>L</td></tr>
    <tr><td>clearance:</td><td>27</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pimavanserin is an atypical antipsychotic agent, acting as a selective serotonin 5-HT2A receptor inverse agonist. It is primarily used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The drug is approved by the FDA and is currently in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects following oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05AX17 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Pimavanserin;
